Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 37 - Drugs for immunological or allergic disorders
Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
11/2003
11/06/2003WO2002045708A9 Use of zwitterionic polysaccharides for the specific modulation of immune processes
11/06/2003WO2002044210A3 Novel human nucleic acid molecules and polypeptides encoding a novel human ion channel expressed in spinal cord and brain
11/06/2003WO2002030257A3 Normalization of defective t cell responsiveness through manipulation of thymic regeneration
11/06/2003WO2002024891A9 B7-like molecules and uses thereof
11/06/2003WO2002024883A3 Lactic acid bacteria capable of reducing an individual's tendency to develop allergic reactions
11/06/2003US20030208249 Energy-activated targeted cancer therapy
11/06/2003US20030208079 Heterocyclic amines such as (2S,3S)-3-((1R)-6-methoxy-1-methyl -1-trifluoromethylisochroman-7-yl)methylamino-2-phenyl piperidine, used as analgesics, antiinflammatory agents, or for proph7ylaxis of cardiovascular disorders
11/06/2003US20030208067 Inhibitors of protein kinase for the treatment of disease
11/06/2003US20030208058 B7-like polypeptides and polynucleotides
11/06/2003US20030208046 Pseudo native chemical ligation
11/06/2003US20030207939 Novel 3-substituted urea derivatives and medicinal use thereof
11/06/2003US20030207931 Use of 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1h-1,2,4-triazole for the treatment of autoimmune diseases
11/06/2003US20030207923 Treatment of autoimmune disease, inflammation and allergy; inhibits release of tumour necrosis factor
11/06/2003US20030207911 For treatment of disease associated with the adenosine A2 receptor such as Alzheimer's disease and Parkinson's disease
11/06/2003US20030207906 Chemical compounds
11/06/2003US20030207902 Heterocyclic compounds useful as inhibitors of tyrosine kinases
11/06/2003US20030207895 Tissue factor antagonists and methods of use thereof
11/06/2003US20030207893 Antihistamines such as (5-Chloro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone, used as antiinflammatory, antiarthritic or bronchodilator agents and/or immunology modulators
11/06/2003US20030207892 Heterocyclic amines such as N-(Pyridin-4-yl)-(1-(4-fluoro-benzyl)indol-3-yl)glyoxylamide, used for prophylaxis of skin disorders, rheumatic diseases or arthritis
11/06/2003US20030207883 Indazole benzimidazole compounds
11/06/2003US20030207879 Preferential G protein coupled receptor antagonists, such as 8-(3-amino-1-methyl-1H-pyrazol-5-yl)-1,3-dipropyl-3,7-dihydro -1H-purine-2,6-dione, used for prophylaxis of asthma, autoimmune diseases or retinopathy
11/06/2003US20030207870 Aryl ureas with angiogenisis inhibiting activity
11/06/2003US20030207866 Drugs useful for the treatment of diseases or disorders of the central nervous system.
11/06/2003US20030207850 Hormone replacement therapy
11/06/2003US20030207847 Dietary calcium as a supplement to vitamin D compound treatment of multiple sclerosis
11/06/2003US20030207846 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
11/06/2003US20030207823 Novel diabetes imaging probes
11/06/2003US20030207812 Cd45 inhibitors
11/06/2003US20030207798 Hair growth promoting agent including a cyclosporin derivative as an active ingredient, and more particularly, a hair growth promoting agent including a cyclosporin A derivative substituted in the 3-position as an active ingredient.
11/06/2003US20030207434 Phosphodiesterases
11/06/2003US20030207403 For diagnosis or treatment of diseases with beta 10 polypeptides and alpha 2/ beta 10 heterodimers or their respective binding agents, such as thyroid gland disorders
11/06/2003US20030207318 Kinesin-like motor protein
11/06/2003US20030207309 Diagnostics and therapeutics for macular degeneration-related disorders
11/06/2003US20030207299 Involves nucleic acid and amino acid sequences of human kinases; used in the diagnosis, treatment, and prevention of cancer, immune disorders, disorders affecting growth and development, cardiovascular diseases, and lipid disorders
11/06/2003US20030207291 Human apoptosis-associated genes and human apoptosis-associated proteins produced thereby
11/06/2003US20030207263 Method of screening therapeutic agents
11/06/2003US20030207262 Compounds, methods of screening, and in vitro and in vivo uses involving anti-apoptotic genes and anti-apoptotic gene products
11/06/2003US20030206967 Sodium metasilicate, borax,sodium thiosulfate, potassium carbonate, refined cane sugar and water; improvement in disease resistance, weight gain rate, crop yield, crop quality, and harvest time
11/06/2003US20030206949 Dispersible phospholipid stabilized microparticles
11/06/2003US20030206930 Soft gelatin capsule manufacture
11/06/2003US20030206926 Characterized by the loss of its capability to reproductively replicate in human cell lines.
11/06/2003US20030206923 Combination of soybean, mushroom and mung bean provides phytoestrogens, beta-glucans, saponins, inositol hexaphosphate, and lectins.
11/06/2003US20030206922 Siderophore receptor polypeptides (SRPs) and porins from gram negative microbes and no greater than 10.0 endotoxin units per milliliter lipopolysaccharide; or SRPs isolated from a gram positive microbe; treating infectious diseases in cattle
11/06/2003US20030206917 Transferring a protein to a cell by coating the cell surface with a lipidated protein; and contacting said cell with a fusion protein having affinity for said lipidated protein and capable of binding to a cell surface receptor
11/06/2003US20030206914 Synthetic antigens for CD1-restricted immune responses
11/06/2003US20030206911 Modifying selected antibodies with biotin and streptavidin, conjugating these antibodies with an effector molecule, and delivering the conjugated effector to an intracellular target
11/06/2003US20030206898 Use of anti-TNFalpha antibodies and another drug
11/06/2003US20030206869 Delivery of antidepressants through an inhalation route
11/06/2003US20030206868 Immune response modifier compounds for treatment of th2 mediated and related diseases
11/06/2003US20030206861 Uses of diterpenoid triepoxides as an antiproliferative agent
11/06/2003CA2827114A1 Multi plasmid system for the production of influenza virus
11/06/2003CA2483819A1 Non-immunosuppressive imunogenic or vaccine composition comprising a mutated e7 protein of the hpv-16 virus
11/06/2003CA2483551A1 Immunogenic agent therapy using plasmapheresis or exchange transfusion
11/06/2003CA2483515A1 Novel thiol derivative, method for producing the same and use thereof
11/06/2003CA2483505A1 Circular dumbbell decoy oligodeoxynucleotides (cdodn) containing dna bindings sites of transcription
11/06/2003CA2483504A1 4,4-(disubstituted)piperidine derivatives with ccr3 antagonism
11/06/2003CA2483500A1 Pyrimidine-2, 4, 6-trione metallo-proteinase inhibitors
11/06/2003CA2483468A1 Mutated hpv-16 e7 polypeptide, pharmaceutical composition comprising it and its preparation process
11/06/2003CA2483441A1 Mannose binding lectin and uses thereof
11/06/2003CA2483314A1 Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
11/06/2003CA2483253A1 Use of compounds having ccr antagonism
11/06/2003CA2483106A1 Decoys for treating and/or preventing th2 cytokine-related allergic diseases, gata3 mutant proteins and, pharmaceutical compositions comprising the decoys and the proteins
11/06/2003CA2483092A1 Tolterodine salts
11/06/2003CA2483091A1 3-substituted amino-1h-indole-2-carboxylic acid and 3-substituted amino-benzo' b! thiophene-2-carboxylic acid derivatives as interieukin-4 gene expression inhibitors
11/06/2003CA2483075A1 Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors
11/06/2003CA2482930A1 Epha2 antigen t epitopes
11/06/2003CA2480845A1 Adipocyte complement related protein zacrp8
11/06/2003CA2480497A1 Substituted pyrazine derivatives
11/06/2003CA2480092A1 N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
11/05/2003EP1359147A1 4,4-disubstituted-1,4-dihydro-2H-3,1-benzoxazin-2-ones useful as HIV reverse transcriptase inhibitors and processes for making the same
11/05/2003EP1359139A1 Terphenyl compounds bearing substituted amino groups
11/05/2003EP1358885A1 Antiallergic agents
11/05/2003EP1358882A1 Use of estriol sulfamate prodrugs for the treatment of autoimmune diseases
11/05/2003EP1358881A1 Use of biogenic estriol diester prodrugs for the treatment of autoimmune diseases
11/05/2003EP1358332A2 A serpin in bifidobacteria
11/05/2003EP1358330A2 Transporters and ion channels
11/05/2003EP1358329A2 Lipid-associated molecules
11/05/2003EP1358326A2 Proteins associated with cell growth, differentiation, and death
11/05/2003EP1358325A2 Protein modification and maintenance molecules
11/05/2003EP1358323A2 Regulators of apoptosis
11/05/2003EP1358209A2 Crystallization of igf-1
11/05/2003EP1358208A2 Sequences upstream of the carp gene, vectors containing them and uses thereof
11/05/2003EP1358203A2 Methods and compositions for use in spliceosome mediated rna trans-splicing
11/05/2003EP1358188A2 Antagonists of mcp-1 function and methods of use thereof
11/05/2003EP1358186A1 Laulimalide derivatives
11/05/2003EP1358182A1 Diazocine derivatives and their use as tryptase inhibitors
11/05/2003EP1358178A2 Sulfonamide lactam inhibitors of factor xa
11/05/2003EP1358175A2 Phenoxy substituted benzocondensed heteroaryl derivatives as thyroid receptor ligands
11/05/2003EP1358171A2 Novel urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use
11/05/2003EP1358161A2 N-pyridyl carboxamide derivatives and pharmaceutical compositions containing them
11/05/2003EP1357978A2 Hematopoietic stem cell gene therapy
11/05/2003EP1357944A2 Perylenequinones for use with immunotherapy agents
11/05/2003EP1357943A2 Methods and compositions for modulating the immune system of animals
11/05/2003EP1357942A2 Methods and compositions for treatment of immune dysfunction disorders
11/05/2003EP1357929A2 Modulation of immune response and methods based thereon
11/05/2003EP1357925A2 Compositions containing an active fraction isolated from hedyotis diffusae and methods of use
11/05/2003EP1357921A2 Bacterial isolates from organisms that respire at least partially through their skin and biologically active extracts derived therefrom
11/05/2003EP1357915A2 PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO 4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS
11/05/2003EP1357909A1 Il-8 receptor antagonists
11/05/2003EP1357904A2 Use of pyrazolo 4,3-d]pyrimidines
1 ... 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 ... 1172